These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 20674350)

  • 1. Discovery of imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
    Belanger DB; Curran PJ; Hruza A; Voigt J; Meng Z; Mandal AK; Siddiqui MA; Basso AD; Gray K
    Bioorg Med Chem Lett; 2010 Sep; 20(17):5170-4. PubMed ID: 20674350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and SAR studies of imidazo-[1,2-a]-pyrazine Aurora kinase inhibitors with improved off-target kinase selectivity.
    Voss ME; Rainka MP; Fleming M; Peterson LH; Belanger DB; Siddiqui MA; Hruza A; Voigt J; Gray K; Basso AD
    Bioorg Med Chem Lett; 2012 May; 22(10):3544-9. PubMed ID: 22503250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
    Belanger DB; Williams MJ; Curran PJ; Mandal AK; Meng Z; Rainka MP; Yu T; Shih NY; Siddiqui MA; Liu M; Tevar S; Lee S; Liang L; Gray K; Yaremko B; Jones J; Smith EB; Prelusky DB; Basso AD
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6739-43. PubMed ID: 20855207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioisosteric approach to the discovery of imidazo[1,2-a]pyrazines as potent Aurora kinase inhibitors.
    Meng Z; Kulkarni BA; Kerekes AD; Mandal AK; Esposite SJ; Belanger DB; Reddy PA; Basso AD; Tevar S; Gray K; Jones J; Smith EB; Doll RJ; Siddiqui MA
    Bioorg Med Chem Lett; 2011 Jan; 21(1):592-8. PubMed ID: 21075632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potency switch between CHK1 and MK2: discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.
    Meng Z; Ciavarri JP; McRiner A; Zhao Y; Zhao L; Reddy PA; Zhang X; Fischmann TO; Whitehurst C; Arshad Siddiqui M
    Bioorg Med Chem Lett; 2013 May; 23(10):2863-7. PubMed ID: 23587425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.
    Martínez González S; Hernández AI; Varela C; Rodríguez-Arístegui S; Alvarez RM; García AB; Lorenzo M; Rivero V; Oyarzabal J; Rabal O; Bischoff JR; Albarrán M; Cebriá A; Alfonso P; Link W; Fominaya J; Pastor J
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1874-8. PubMed ID: 22325943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design of imidazo[1,2-a]pyrazine derivatives as selective inhibitors of Aurora-A kinase in cells.
    Bouloc N; Large JM; Kosmopoulou M; Sun C; Faisal A; Matteucci M; Reynisson J; Brown N; Atrash B; Blagg J; McDonald E; Linardopoulos S; Bayliss R; Bavetsias V
    Bioorg Med Chem Lett; 2010 Oct; 20(20):5988-93. PubMed ID: 20833547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors.
    Jin M; Wang J; Kleinberg A; Kadalbajoo M; Siu KW; Cooke A; Bittner MA; Yao Y; Thelemann A; Ji Q; Bhagwat S; Mulvihill KM; Rechka JA; Pachter JA; Crew AP; Epstein D; Mulvihill MJ
    Bioorg Med Chem Lett; 2013 Feb; 23(4):979-84. PubMed ID: 23317569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.
    Mortensen DS; Perrin-Ninkovic SM; Harris R; Lee BG; Shevlin G; Hickman M; Khambatta G; Bisonette RR; Fultz KE; Sankar S
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6793-9. PubMed ID: 21978683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.
    Robarge KD; Lee W; Eigenbrot C; Ultsch M; Wiesmann C; Heald R; Price S; Hewitt J; Jackson P; Savy P; Burton B; Choo EF; Pang J; Boggs J; Yang A; Yang X; Baumgardner M
    Bioorg Med Chem Lett; 2014 Oct; 24(19):4714-4723. PubMed ID: 25193232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based drug design of novel Aurora kinase A inhibitors: structural basis for potency and specificity.
    Coumar MS; Leou JS; Shukla P; Wu JS; Dixit AK; Lin WH; Chang CY; Lien TW; Tan UK; Chen CH; Hsu JT; Chao YS; Wu SY; Hsieh HP
    J Med Chem; 2009 Feb; 52(4):1050-62. PubMed ID: 19140666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aurora kinase inhibitors based on the imidazo[1,2-a]pyrazine core: fluorine and deuterium incorporation improve oral absorption and exposure.
    Kerekes AD; Esposite SJ; Doll RJ; Tagat JR; Yu T; Xiao Y; Zhang Y; Prelusky DB; Tevar S; Gray K; Terracina GA; Lee S; Jones J; Liu M; Basso AD; Smith EB
    J Med Chem; 2011 Jan; 54(1):201-10. PubMed ID: 21128646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors.
    Zeng H; Belanger DB; Curran PJ; Shipps GW; Miao H; Bracken JB; Arshad Siddiqui M; Malkowski M; Wang Y
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5870-5. PubMed ID: 21855335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a new series of Aurora inhibitors through truncation of GSK1070916.
    Medina JR; Grant SW; Axten JM; Miller WH; Donatelli CA; Hardwicke MA; Oleykowski CA; Liao Q; Plant R; Xiang H
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2552-5. PubMed ID: 20335034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinases.
    Matthews TP; McHardy T; Klair S; Boxall K; Fisher M; Cherry M; Allen CE; Addison GJ; Ellard J; Aherne GW; Westwood IM; van Montfort R; Garrett MD; Reader JC; Collins I
    Bioorg Med Chem Lett; 2010 Jul; 20(14):4045-9. PubMed ID: 20561787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based lead identification of ATP-competitive MK2 inhibitors.
    Barf T; Kaptein A; de Wilde S; van der Heijden R; van Someren R; Demont D; Schultz-Fademrecht C; Versteegh J; van Zeeland M; Seegers N; Kazemier B; van de Kar B; van Hoek M; de Roos J; Klop H; Smeets R; Hofstra C; Hornberg J; Oubrie A
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3818-22. PubMed ID: 21565500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification, SAR studies, and X-ray co-crystallographic analysis of a novel furanopyrimidine aurora kinase A inhibitor.
    Coumar MS; Tsai MT; Chu CY; Uang BJ; Lin WH; Chang CY; Chang TY; Leou JS; Teng CH; Wu JS; Fang MY; Chen CH; Hsu JT; Wu SY; Chao YS; Hsieh HP
    ChemMedChem; 2010 Feb; 5(2):255-67. PubMed ID: 20039358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure activity relationship studies of imidazo[1,2-a]pyrazine derivatives against cancer cell lines.
    Myadaraboina S; Alla M; Saddanapu V; Bommena VR; Addlagatta A
    Eur J Med Chem; 2010 Nov; 45(11):5208-16. PubMed ID: 20832916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases.
    McClellan WJ; Dai Y; Abad-Zapatero C; Albert DH; Bouska JJ; Glaser KB; Magoc TJ; Marcotte PA; Osterling DJ; Stewart KD; Davidsen SK; Michaelides MR
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5620-4. PubMed ID: 21778056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imidazo[1,2-a]pyrazine diaryl ureas: inhibitors of the receptor tyrosine kinase EphB4.
    Mitchell SA; Danca MD; Blomgren PA; Darrow JW; Currie KS; Kropf JE; Lee SH; Gallion SL; Xiong JM; Pippin DA; DeSimone RW; Brittelli DR; Eustice DC; Bourret A; Hill-Drzewi M; Maciejewski PM; Elkin LL
    Bioorg Med Chem Lett; 2009 Dec; 19(24):6991-5. PubMed ID: 19879134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.